Evidence map›Paper›PMID 42369587›Full record

ArticleNeuroMarkers2026

Spontaneous Isomerization of Tau is Most Prevalent in Alzheimer's Disease.

Evan E Hubbard, Kevin Reagle, Matthew K Lui, Maxence Derbez-Morin, Gennifer E Merrihew, Michael J MacCoss, Ryan R Julian

Abstract read
In one paragraph

Article in NeuroMarkers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evan E HubbardDepartment of Chemistry, University of California, Riverside, California 92521, United States, Department of Genome Sciences, University of Washington, Seattle, Washington 98195, United States.
Kevin ReagleDepartment of Chemistry, University of California, Riverside, California 92521, United States, Department of Genome Sciences, University of Washington, Seattle, Washington 98195, United States.
Matthew K LuiDepartment of Chemistry, University of California, Riverside, California 92521, United States, Department of Genome Sciences, University of Washington, Seattle, Washington 98195, United States.
Maxence Derbez-MorinDepartment of Chemistry, University of California, Riverside, California 92521, United States, Department of Genome Sciences, University of Washington, Seattle, Washington 98195, United States.
Gennifer E MerrihewDepartment of Chemistry, University of California, Riverside, California 92521, United States, Department of Genome Sciences, University of Washington, Seattle, Washington 98195, United States.
Michael J MacCossDepartment of Chemistry, University of California, Riverside, California 92521, United States, Department of Genome Sciences, University of Washington, Seattle, Washington 98195, United States.
Ryan R JulianDepartment of Chemistry, University of California, Riverside, California 92521, United States, Department of Genome Sciences, University of Washington, Seattle, Washington 98195, United States.

Funding

Project 4: Novel reagent development to enable molecular characterizationU19AG065156 · NIA · UNIVERSITY OF WASHINGTON · PI TIAN, LU · 2020 to 2024
$15.9M
Molecular Phenotyping in Alzheimer's DiseaseRF1AG053959 · NIA · STANFORD UNIVERSITY · PI LARSON, ERIC B, MACCOSS, MICHAEL · 2016 to 2017
$4.1M
Connecting long-lived protein isomerization to lysosomal failure in Alzheimer's diseaseR01AG066626 · NIA · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI JULIAN, RYAN ROY · 2020 to 2024
$2.8M
NIA NIH HHS R01 AG066626NIA NIH HHS RF1 AG053959NIA NIH HHS U19 AG065156
6 · The paper itself

Abstract

Alzheimer's disease is the most common cause of dementia in humans and has been the subject of intense study for decades. Despite these efforts, the precise underlying cause or causes of Alzheimer's disease have remained elusive. Here we implement novel analysis of mass-spectrometry derived proteomics data to examine an understudied phenomenon related to Alzheimer's disease, isomerization of the protein tau. Isomerization is a spontaneous chemical modification that occurs in long-lived proteins and evolves most rapidly at aspartic acid. Recent results have demonstrated that isomerization of tau is more prevalent in Alzheimer's disease relative to healthy controls. To further map out the importance of tau isomerization in neurodegeneration, we examined its prevalence in several additional diseases by mining publicly available datasets and our own results, allowing for examination of Parkinson's disease, Lewy body dementia, vascular brain injury, and chronic traumatic encephalopathy. To evaluate the extent of tau isomerization in various locations within the brain in Alzheimer's disease, we examined samples from the frontal cortex, anterior cingulate gyrus, inferior parietal lobule, and caudate. Interestingly, our results demonstrate that significant isomerization of tau occurs only in individuals with Alzheimer's disease. In terms of localization, tau was easily detected in all regions of the brain, and tau isomerization was detected for Alzheimer's disease in all regions except the caudate. Importantly, tau isomerization can be easily and rigorously quantified from proteomics data. Comparison of the extent of tau isomerization with pre-mortem performance on the Mini-Mental State Examination revealed strong correlation. In addition to minimal abundance in other forms of neurodegeneration, tau isomerization was also low for a small number of the individuals designated to have Alzheimer's disease in our study, however consideration of other factors such as genetic predisposition, age, and mental acuity also differentiates these individuals. Importantly, the amount of tau isomerization observed in our studies does not correlate in any meaningful way with tau aggregation. Collectively, these observations suggest that tau isomerization derives from a different pathogenesis than other neurodegenerative markers, one that is only prevalent in Alzheimer's disease and may offer means for delineating the underlying causes of the disease.

Indexed as

Alzheimer’s DiseaseIsomerizationProteomics

Identifiers

PMID42369587
PMCPMC13309227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.